Leukemia

As wide receiver John Metchie returns to the field after cancer experience, and coach Brent Venables announces wife’s cancer diagnosis, this is what’s happening in the oncology space this week.

As Ben Alldis reveals previous cancer diagnosis and Luke Combs brings a Make-a-Wish cancer survivor on stage during a concert venue, this is what’s occurring in the oncology space this week.

The Food and Drug Administration approved a Vanflyta regimen for patients with FLT-ITD—positive acute myeloid leukemia.

A recent study has determined that Xospata plus chemo is safe for the treatment of relapsed/refractory acute myeloid leukemia with an FLT3 mutation.

Singer-songwriter Andrew McMahon is not the same person he was before his leukemia diagnosis, and that’s OK, he said.

There was no major difference in progression-free survival between patients with relapsed/refractory chronic lymphocytic leukemia who were treated with Calquence or Brukinsa.

Musician Andrew McMahon has made it his mission to spread the message of community and seeking mental health care like therapy for adolescents and young adults with cancer.

The full approval is based on data showing that 80% of patients with B-ALL experienced a complete MRD response.

Findings from a phase 3 trial demonstrated that half of patients with FLT3-ITD-mutant acute myeloid leukemia and detectable minimal residual risk derived a relapse-free survival benefit with Xospata.

Lasting guilt gets no one anywhere — especially when it comes to cancer.

The CAR-T cell therapy, Tecartus, improved outcomes for patients with B-cell acute lymphoblastic leukemia, offering a promising standard of care for this patient population.

Three-fourths of patients with relapsed/refractory B-cell acute lymphoblastic leukemia experienced complete responses — which tended to be durable — when treated with the CAR-T cell therapy, Obe-cel.

From a teen cancer survivor being gifted tickets to Taylor Swift’s ‘Eras’ tour to Michael Hendry backing out of the US Open due to a leukemia diagnosis, here’s what’s happening in the oncology space this week.

Cryopreserved stem cells led to a higher rate of relapse in patients with blood cancer, though there was no difference in survival, research showed.

Lori A. Leslie, MD, and Hoshiyuki Iida, APN, offer closing thoughts on the future treatment landscape of chronic lymphocytic leukemia.

Experts on chronic lymphocytic leukemia discuss how to approach cost considerations and available resources for CLL treatments.

Insights on supportive care and approaches to managing adverse effects of BTK inhibitors in the treatment of chronic lymphocytic leukemia.

Bariatric surgery may reduce the body’s way of absorbing drugs for chronic myeloid leukemia, research showed.

Omisirge is an umbilical cord blood-based therapy that may prevent infection in patients with blood cancer undergoing stem cell transplant.

CLL expert Lori A. Leslie, MD, gives a comprehensive overview of the ALPINE and ELEVATE-RR head-to-head studies of BTK inhibitors in CLL.

Lori A. Leslie, MD, an expert on CLL, talks about factors that influence treatment decisions.

After leaving the hospital, I craved the security and support my cancer care team provided me.

CLL experts offer insights on shared decision-making with patients while selecting treatments.

Lori A. Leslie, MD, an expert on chronic lymphocytic leukemia, provides a comprehensive overview of BTK inhibitors used in the treatment of CLL.

Hoshiyuki Iida, APN, discusses his role in the multidisciplinary team in the treatment of patients with chronic lymphocytic leukemia.